Elevated expression of PSMC2 has been observed in gliomas and is associated with a poor prognosis for patients with this disease [52]; inhibition of PSMC2 can inhibit the cancer progression and drug resistance through regulation of immune microenvironment and cell autophagy [53, 54]. The gene discussed is PSMC2; the disease is cancer.